European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds
/PRNewswire/ -- The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel...